PFIZER Q2 : STANDALONE NET PROFIT UP 65.7% AT ₹313.25 CR (YOY), UP 53.2% (QOQ). GOOD (ON 1ST LOOK)

Revenue up 13.2% at ₹726.86 Cr (YOY), up 11.3% (QOQ). Ebitda up 13.5% at ₹308.53 Cr (YOY), up 5.5% (QOQ); margins 42.5% v 42.3% (YOY), 44.8% (QOQ). Caution: Q2 includes exceptional gain of ₹132.06 Cr from Pfizer Inc USA on Minipress XL discontinuation. Impact: Reported profit boosted by one-off exceptional gain; underlying operating growth modest.

Pfizer Limited

Open attachment

← Back to feed